CommercialPrior AuthHigh impact
Gonadotropin-Releasing Hormone Analogs and Antagonists (CPB 0501, reviewed 2026-07-10)
Aetna·Oncology, OB-GYN, Endocrinology +2 more·Medical Policy
Effective date
Jul 10, 2026
We identified it
Aug 15, 2026
Summary
Aetna updated its Clinical Policy Bulletin 0501 (effective 2026-07-10) establishing coverage criteria for gonadotropin-releasing hormone analogs and antagonists across multiple indications including prostate cancer, breast cancer, endometriosis, ovarian cancer, gender dysphoria, and others. Key changes include: (1) precertification requirement for prostate cancer products, (2) expanded gender dysphoria coverage with specific provider specialization requirements, and (3) detailed continuation-of-therapy criteria requiring clinical benefit documentation for reauthorization.
Action Required
IMMEDIATE ACTIONS REQUIRED: (1) Billing team must implement precertification protocol for all gonadotropin-releasing hormone products when billed for prostate cancer indication using Aetna's specialty pharmacy precertification system (contact: 866-752-7021 or fax 888-267-3277). Update billing software to flag prostate cancer diagnoses for mandatory prior auth before claim submission. (2) Establish verification process to confirm prescribing provider specialization for gender dysphoria cases (pediatric endocrinologist, family medicine, internal medicine, or OB-GYN with mental health collaboration for members <18). Claims lacking documented provider specialization will be denied. (3) Update reauthorization request templates to require clinical benefit documentation: for prostate cancer specify serum testosterone <50 ng/dL; for breast cancer/ovarian cancer document absence of disease progression or unacceptable toxicity. Implement in EHR and billing system. (4) Prior to processing any gender dysphoria claims, verify member age, Tanner staging, comorbidity control, and documented fertility preservation counseling—missing elements will result in denial. (5) Billing staff must cross-reference member benefit plans to confirm advanced reproductive technology coverage before approving cetrorelix acetate or ganirelix acetate for ART/ovulation induction; non-covered plans should result in patient notification. Failure to implement precertification and provider specialization verification will result in claim denials and compliance violations.